This article highlights recent research on breast cancer, lung cancer, melanoma, head and neck cancer, and hematologic malignancies.

The National Institutes of Health (NIH) can continue withholding funding for terminated research grants, the Supreme Court has ruled. 1,2 The court’s decision allows the NIH to withhold the funding ...

The main implication of our study is support for incorporating quadruplet regimens into new guidelines for the management of transplant-ineligible patients newly diagnosed multiple myeloma,” the ...

The “early promising clinical outcomes” provide a strong basis for further investigation of upright image-guided adaptive proton therapy, according to researchers.

“he introduction of effective cancer innovations increased population-level health among patients with advanced lung cancer and melanoma but also widened the survival gap across county-level income ...

An analysis of more than 13 million EHR notes revealed evidence suggesting racial bias in how doctors document patient credibility.

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to ifinatamab deruxtecan (I-DXd) for the treatment of adults with extensive-stage small cell lung cancer (ES-SCLC ...

Only patients who received rituximab, ipilimumab plus nivolumab, and trastuzumab plus pertuzumab had infusion-related reactions in the real-world cohort.

The ASPR must update its 2022 list of 86 essential medicines and provide a plan to store and maintain a 6-month supply of APIs for drugs on the updated list, the order states.

Subspecialization in oncology is increasing in the United States, but it varies across cancer types and regions, data suggest.

The FDA has granted fast track designation to HLD-0915 for the treatment of metastatic castration-resistant prostate cancer.

The FDA has accepted for review the NDA for vepdegestrant to treat ESR1-mutated, ER+, HER2- advanced breast cancer.